AI assistant
Axogen, Inc. — Director's Dealing 2023
Feb 2, 2023
32414_dirs_2023-02-01_254334b0-e2ad-49d1-aaf9-a939d5df69c8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2023-01-30
Reporting Person: MARIANI PETER J (EVP & Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-30 | Common Stock | M | 20939 | $5.04 | Acquired | 63047 | Direct |
| 2023-01-30 | Common Stock | S | 14111 | $9.69 | Disposed | 48936 | Direct |
| 2023-01-31 | Common Stock | M | 20939 | $5.04 | Acquired | 69875 | Direct |
| 2023-01-31 | Common Stock | S | 14320 | $9.55 | Disposed | 55555 | Direct |
| 2023-02-01 | Common Stock | M | 20940 | $5.04 | Acquired | 76495 | Direct |
| 2023-02-01 | Common Stock | S | 14550 | $9.36 | Disposed | 61945 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-30 | Employee Stock Option (right to purchase) | $5.04 | M | 20939 | Disposed | 2023-03-01 | Common Stock (20939.0) | Direct |
| 2023-01-31 | Employee Stock Option (right to purchase) | $5.04 | M | 20939 | Disposed | 2023-03-01 | Common Stock (20939.0) | Direct |
| 2023-02-01 | Employee Stock Option (right to purchase) | $5.04 | M | 20940 | Disposed | 2023-03-01 | Common Stock (20940.0) | Direct |
Footnotes
F1: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.36 to $9.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.